Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected resultsBreast cancer research and treatment, 2017-02, Vol.161 (3), p.575-586 [Peer Reviewed Journal]The Author(s) 2016 ;COPYRIGHT 2017 Springer ;Breast Cancer Research and Treatment is a copyright of Springer, 2017. ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-016-4085-4 ;PMID: 28008555 ;CODEN: BCTRD6Full text available |
|
2 |
Material Type: Article
|
Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patientsBreast cancer research and treatment, 2013-01, Vol.137 (2), p.465-470 [Peer Reviewed Journal]Springer Science+Business Media New York 2012 ;2014 INIST-CNRS ;COPYRIGHT 2013 Springer ;Springer Science+Business Media New York 2013 ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-012-2355-3 ;PMID: 23224235 ;CODEN: BCTRD6Full text available |
|
3 |
Material Type: Article
|
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortBritish journal of cancer, 2019-12, Vol.121 (12), p.991-1000 [Peer Reviewed Journal]Copyright Nature Publishing Group Dec 2019 ;The Author(s), under exclusive licence to Cancer Research UK 2019 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-019-0619-y ;PMID: 31719684Full text available |
|
4 |
Material Type: Article
|
The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersCancer cell, 2018-09, Vol.34 (3), p.427-438.e6 [Peer Reviewed Journal]2018 Elsevier Inc. ;Copyright © 2018 Elsevier Inc. All rights reserved. ;ISSN: 1535-6108 ;EISSN: 1878-3686 ;DOI: 10.1016/j.ccell.2018.08.008 ;PMID: 30205045Full text available |
|
5 |
Material Type: Article
|
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research GroupJournal of clinical oncology, 2021-10, Vol.39 (28), p.3171-3181 [Peer Reviewed Journal]2021 by American Society of Clinical Oncology 2021 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.21.00944 ;PMID: 34357781Full text available |
|
6 |
Material Type: Article
|
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerJournal of clinical oncology, 2017-07, Vol.35 (19), p.2141-2148 [Peer Reviewed Journal]2017 by American Society of Clinical Oncology 2017 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2016.70.8297 ;PMID: 28291390Full text available |
|
7 |
Material Type: Article
|
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trialThe lancet oncology, 2017-06, Vol.18 (6), p.743-754 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 1, 2017 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30313-3 ;PMID: 28526538Full text available |
|
8 |
Material Type: Article
|
Genomic Characterization of de novo Metastatic Breast CancerClinical cancer research, 2021-02, Vol.27 (4), p.1105-1118 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-20-1720 ;PMID: 33293374Full text available |
|
9 |
Material Type: Article
|
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trialThe lancet oncology, 2017-06, Vol.18 (6), p.732-742 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jun 1, 2017 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(17)30312-1 ;PMID: 28526536Full text available |
|
10 |
Material Type: Article
|
Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant ChemotherapyAnnals of surgical oncology, 2018-09, Vol.25 (9), p.2596-2602 [Peer Reviewed Journal]Society of Surgical Oncology 2018 ;Annals of Surgical Oncology is a copyright of Springer, (2018). All Rights Reserved. ;ISSN: 1068-9265 ;EISSN: 1534-4681 ;DOI: 10.1245/s10434-018-6637-9 ;PMID: 29978369Full text available |
|
11 |
Material Type: Article
|
Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case SeriesThe oncologist (Dayton, Ohio), 2015-06, Vol.20 (6), p.586-592 [Peer Reviewed Journal]2015 AlphaMed Press ;AlphaMed Press. ;AlphaMed Press 2015 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1634/theoncologist.2014-0243 ;PMID: 25948676Full text available |
|
12 |
Material Type: Article
|
Omission of adjuvant radiotherapy in low-risk elderly males with breast cancerBreast cancer (Tokyo, Japan), 2024-05, Vol.31 (3), p.485-495 [Peer Reviewed Journal]The Author(s) 2024 ;2024. The Author(s). ;ISSN: 1340-6868 ;EISSN: 1880-4233 ;DOI: 10.1007/s12282-024-01560-y ;PMID: 38507145Digital Resources/Online E-Resources |
|
13 |
Material Type: Article
|
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERsClinical cancer research, 2020-03, Vol.26 (5), p.1105-1113 [Peer Reviewed Journal]2020 American Association for Cancer Research. ;ISSN: 1078-0432 ;EISSN: 1557-3265 ;DOI: 10.1158/1078-0432.CCR-19-2350 ;PMID: 31772121Full text available |
|
14 |
Material Type: Article
|
Prognostic factors in male breast cancer: a population-based studyBreast cancer research and treatment, 2016-04, Vol.156 (3), p.539-548 [Peer Reviewed Journal]Springer Science+Business Media New York 2016 ;COPYRIGHT 2016 Springer ;ISSN: 0167-6806 ;EISSN: 1573-7217 ;DOI: 10.1007/s10549-016-3768-1 ;PMID: 27039306 ;CODEN: BCTRD6Full text available |
|
15 |
Material Type: Article
|
The prognostic significance of tumour―stroma ratio in oestrogen receptor-positive breast cancerBritish journal of cancer, 2014-04, Vol.110 (7), p.1744-1747 [Peer Reviewed Journal]2015 INIST-CNRS ;Copyright Nature Publishing Group Apr 1, 2014 ;Copyright © 2014 Cancer Research UK 2014 Cancer Research UK ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/bjc.2014.69 ;PMID: 24548861 ;CODEN: BJCAAIFull text available |
|
16 |
Material Type: Article
|
Adjuvant systemic therapy for male breast carcinomaCancer, 2005-12, Vol.104 (11), p.2359-2364 [Peer Reviewed Journal]Copyright © 2005 American Cancer Society ;2006 INIST-CNRS ;ISSN: 0008-543X ;EISSN: 1097-0142 ;DOI: 10.1002/cncr.21526 ;PMID: 16270318 ;CODEN: CANCARDigital Resources/Online E-Resources |
|
17 |
Material Type: Article
|
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)Annals of oncology, 2019-05, Vol.30 (5), p.766-773 [Peer Reviewed Journal]2019 THE AUTHORS ;The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019 ;The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. ;ISSN: 0923-7534 ;EISSN: 1569-8041 ;DOI: 10.1093/annonc/mdz061 ;PMID: 30796821Full text available |
|
18 |
Material Type: Article
|
Prognostic relevance of Ki67 expression in primary male breast cancer: determination of cut-off points by different evaluation methods and statistical examinationsJournal of cancer research and clinical oncology, 2022-02, Vol.148 (2), p.441-447 [Peer Reviewed Journal]The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 ;2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. ;The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021. ;ISSN: 0171-5216 ;EISSN: 1432-1335 ;DOI: 10.1007/s00432-021-03623-5 ;PMID: 33991247Full text available |
|
19 |
Material Type: Article
|
Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysisBritish journal of cancer, 2019-02, Vol.120 (3), p.301-305 [Peer Reviewed Journal]This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Cancer Research UK 2019 ;ISSN: 0007-0920 ;EISSN: 1532-1827 ;DOI: 10.1038/s41416-018-0369-2 ;PMID: 30655614Full text available |
|
20 |
Material Type: Article
|
Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer: A population-based studyEuropean journal of cancer (1990), 2017-01, Vol.71, p.7 [Peer Reviewed Journal]Copyright © 2016 Elsevier Ltd. All rights reserved. ;EISSN: 1879-0852 ;DOI: 10.1016/j.ejca.2016.10.038 ;PMID: 27940356Digital Resources/Online E-Resources |